We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Regulator of the Necroptosis Cell Death Pathway Identified

By Biotechdaily staff writers
Posted on 28 Apr 2008
Researchers have found that three small molecules, necrostain-1, -3, and –5 inhibit the activity of the enzyme RIP1 kinase and prevent it from triggering the necroptosis cell death pathway.

Cells are programmed to die when they reach the end of their lifecycle, and that regulated process is called apoptosis. More...
Cells can also be killed through pathways not controlled by apoptosis. Until recently, this type of cell death, termed necrosis, was believed to be unregulated, a type of accidental cell death caused when cells are placed under extreme stress such as during a heart attack, stroke, or organ failure. Recent studies have shown, however, that necrotic cell death (necroptosis) is regulated and has a specific biochemical pathway.

Investigators at Tufts University (Boston, MA, USA) had previously found that three small molecules, necrostatin-1, necrostatin-3, and necrostatin-5 were inhibitors of the necroptosis pathway. The purpose of the current study was to identify the molecular target for necrostatin activity.

The investigators decided to focus on the enzyme RIP1 kinase because it had been previously reported by other groups to be important for necroptosis, and necrostatin-1 looked similar to known kinase inhibitors. Results obtained from in vitro enzyme interaction studies were published in the April 13, 2008, online edition of the journal Nature Chemical Biology.

"Our research found that RIP1 kinase can be inhibited by three small molecules: necrostatin-1, -3 and -5,” said first author Dr. Alexei Degterev, assistant professor of medicine at Tufts University. "Overall, these data establish RIP1 kinase as a new target for therapeutic drug development for human diseases involving necrotic tissue injury, and they establish necrostatins as first-in-class potent and selective inhibitors of RIP1 kinase. Next, research needs to determine the cellular pathway initiated by RIP1 kinase activity, develop better tools to further investigate its role in human disease, and establish how necrostatins are able to prevent RIP1 kinase from signaling the cell to kill itself. This may one day result in effective therapies, currently not available, for many life-threatening diseases.”


Related Links:
Tufts University

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.